MedPage Today) — The FDA approved nivolumab (Opdivo) in combination with chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer (NSCLC), Bristol Myers Squibb announced.
According to the company, the approval…
Read More
